Coronavirus vaccine: Oxford Vaccine

coronavirus vaccine
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email
Share on print

Serum Institute signs deal with Gates Foundation to price Covid -19 vaccine below 250/dose  which converts to be less than US$ 5 / dose.

It will receive  at risk funding of $ 150 million from Bill & Melinda Gates Foundation to manufacture 100 million doses of COVID-19 vaccines for India and low-and-middle income countries. Serum Inida has earlier joined hands with Astra Zeneca and Novavax to develop their COVID-19 candidates. Under this agreement, India-based firm can charge a maximum of $3 per dose for the two COVID-19 vaccines. The vaccine maker will get the funding from the Gates Foundation through international vaccine alliance GAVI.

Novavax Inc  has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.

Oxford’s COVID-19 vaccine has shown a positive result in its initial trial and according to a report published in the BMJ (British medical journal), The Lancet, the COVID-19 vaccine produced a dual immune response in people aged 18 to 55.

On production of the Oxford’s COVID-19 vaccine, Serum India Managing Director, Poonawalla added, “Keeping in mind the pandemic situation, we have two dedicated facilities to produce millions of doses of the COVID-19 vaccine, while withholding vast production of other products.